Skip to main content
. Author manuscript; available in PMC: 2014 Nov 1.
Published in final edited form as: Blood Rev. 2013 Sep 2;27(6):261–267. doi: 10.1016/j.blre.2013.08.002

Figure 3. DKK1-targeted therapies in MBD.

Figure 3

DKK1 secreted by myeloma cells provides us a potentially therapeutic means of intervention in drug discovery. DKK1 targeted therapies, including DKK1 neutralizing antibodies, proteasome inhibitor, vaccine and regulatory factor (e.g. ET-1), have been carried out and all of them have shown many curative clinical benefits on MBD.